Growth across Microbial Solutions and Biologics Testing and CDMO businesses is likely to have contributed to Charles River's (CRL) Q2 revenues, offset by lower biopharmaceutical demand.
WILMINGTON, Mass. & SAN FRANCISCO, July 24, 2024--Charles River and Autobahn Labs announce collaborative program; Charles River CSO Justin Bryans joins Autobahn's Board of Directors
WILMINGTON, Mass., July 16, 2024--Charles River Laboratories schedules second-quarter 2024 earnings release and conference call for Wednesday, August 7th.